Ty -jour t1-严重哮喘管理中的分数呼出一氧化氮（FENO）的临床实用性JF-欧洲呼吸杂志Adel H. Au -Brightling，Christopher E. Y1-2020/01 ur -http：//www.qdcxjkg.com/content/content/early/2020/01/01/03/13993003.016333-2019.1999999.ABSTRACT N2-气道的炎症性疾病，影响了全球超过3.5亿人，并给医疗保健提供者和更广泛的社会带来了重大负担。大约5-10％的哮喘患者被诊断出患有严重哮喘，并且通常与加重，发病率增加，死亡率和更高哮喘相关的医疗费用的住院风险增加有关。一氧化氮（NO）是免疫反应的重要调节剂，是气道中炎症的产物，在哮喘中产生过量。分数呼气NO（FENO）主要用作对吸入皮质类固醇（ICS）的反应的预测指标，以监测没有ICS的患者的依从性和诊断工具。在英国，美国国家卫生与护理研究所（NICE）指南建议使用FENO来初步诊断可疑哮喘患者。在美国，美国胸腔学会（ATS）指南建议FENO作为哮喘初步诊断和监测气道炎症的一部分。Feno也已被证明是哮喘恶化的预测因素，较高的水平与更多的加重有关。另外，较高水平的FENO已显示与肺功能下降有关。 FeNO testing is a cost-effective procedure and has been shown to improve patient management when combined with standard assessment methods. Recent evidence suggests that FeNO may also be useful as a surrogate biomarker for the assessment and management of severe asthma and to predict responsiveness to some biological therapies.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Menzies-Gow reports attending advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi and Teva. He has received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Teva and Vectura, and participated in research for which his host institution has been remunerated by AstraZeneca. He has attended international conferences sponsored by Boehringer Ingelheim and Teva, and has consultancy agreements with AstraZeneca, Sanofi and Vectura.Conflict of interest: Dr. Mansur reports an educational grant for service support from AstraZeneca; and fees for talks and advisory group contribution and conference attendance from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Napp Pharmaceuticals, Novartis, Sanofi , and other outside the submitted work.Conflict of interest: Dr. Brightling reports non-financial support from Sanofi Genzyme Inc., UK, during the conduct of the study; grants from Air-PROM, Medical Research Council UK, and National Institute for Health Research UK; grants and personal fees from 4DPharma, AstraZeneca/Medimmune, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Gossamer, Mologic, Novartis, Roche/Genentech, and Sanofi/Regeneron; personal fees from Gilead, Pfizer, PreP, Teva, Theravance , and Vectura, outside the submitted work. ER -